Although torin-1 showed very promising preclinical efficacy in vitro and in vivo in ALL, due to its short in vivo half-life and low oral bioavailability, novel MTOR enzymatic inhibitors with improved pharmacokinetics are urgently needed [28]. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.